Farther Finance Advisors’s Nektar Therapeutics NKTR Stock Holding History

Farther Finance Advisors’s Portfolio NKTR Stock Details NKTR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$1.82K	Buy	30 +28	+1,400%	+$1.97K	﹤0.01%	5433
2026 Q2	$140	Buy	2 +1	+100%	+$73	﹤0.01%	5760
2026 Q1	$76	Sell	1 -140	-99%	-$7.97K	﹤0.01%	5540
2025 Q4	$5.96K	Buy	+141	New	+$7.89K	﹤0.01%	4206

Other funds holding NKTR

TSC

Two Seas Capital Rye, New York $8.68B AUM 78.08% 1-Year Est. Return

GAMMA Investing Foster City, California $2.96B AUM 34.38% 1-Year Est. Return

VCM

Versant Capital Management Phoenix, Arizona $1.17B AUM 28.44% 1-Year Est. Return

Farther Finance Advisors's NKTR Position: Q3 2026 in Review

Farther Finance Advisors increased its Nektar Therapeutics (NKTR) stake by 1,400% in Q3 2026, buying an estimated $1.97K and bringing the position to 30 shares worth $1.82K. The position accounts for ﹤0.01% of the portfolio, ranked #5433.

Farther Finance Advisors first reported a position in NKTR in Q4 2025 and has held it in 4 quarters since. The position peaked at $5.96K in Q4 2025. 4 funds tracked by Wall St. Rank hold NKTR as of Q3 2026.

Farther Finance Advisors held 30 shares of Nektar Therapeutics worth $1.82K as of Q3 2026.
Farther Finance Advisors bought 28 Nektar Therapeutics shares in Q3 2026, an estimated $1.97K.
Nektar Therapeutics made up ﹤0.01% of Farther Finance Advisors's portfolio in Q3 2026, its #5433 holding.
Farther Finance Advisors first reported a position in Nektar Therapeutics in Q4 2025 and has held it in 4 quarters since.
Farther Finance Advisors's Nektar Therapeutics position peaked at $5.96K in Q4 2025.
4 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q3 2026.

Based on Farther Finance Advisors's 13F filing for Q3 2026, filed 8 Oct 2026.